Difference between revisions of "Yildiz2"
(Tag: Rollback) |
|||
| Line 1: | Line 1: | ||
| − | ==<span style="font-size: 14pt;">The addition of hyperbaric oxygen to antibiotic treatment improved many clinical scores in patients with hydranitis suppurativa </span>== | + | |
| − | ==<span style="font-size: | + | == <span style="font-size: 14pt;">The addition of hyperbaric oxygen to antibiotic treatment improved many clinical scores in patients with hydranitis suppurativa</span> == |
| − | {| | + | |
| − | + | == <span style="font-size:medium;">'''Clinical bottom line:'''</span> == | |
| + | |||
| + | {| | ||
|- | |- | ||
| + | | <span style="font-size:medium;">1. Both groups improved over the course of treatment.<br/> <br/> 2. Patients with adjunctive HBOT had more chance of normalising ESR but not CRP after 10 weeks, as well as improvement in most scores assessed.</span> | ||
|} | |} | ||
| − | |||
| − | <span style="font-size: | + | <span style="font-size:medium;">'''Citation/s: '''1. Yildiz H, Senol L, Ercan E, Bilgili ME, Karabudak Abuaf O. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa. International journal of dermatology. 2016;55(2):232-7.</span> |
| − | + | ||
| + | <span style="font-size:medium;">'''Lead author's name and fax:''' Hamda Yildiz hamzayildiz@gmail.com</span> | ||
| − | <span style="font-size: | + | <span style="font-size:medium;">'''Three-part Clinical Question:''''''For patients with hidradenitis suppurativa, does the addition of HBO to a regimen of antibiotics only, improve the rate of healing?'''</span> |
| − | |||
| − | <span style="font-size: | + | <span style="font-size:medium;">'''Search Terms:''' hydradenitis suppurativa, wound healing,</span> |
| − | <span style="font-size: | + | <span style="font-size:medium;">The Study: '''Non-blinded open randomised controlled trial with intention-to-treat.'''</span> |
| − | <span style="font-size: | + | <span style="font-size:medium;">'''The Study Patients:''' Adult patients newly diagnosed with hydradenitis suppurative (HS)</span> |
| − | + | <span style="font-size:medium;">'''Control group''' (N = 21; 21 analysed): 10 weeks of double therapy with clindamycin (300 mg bd) and rifampicin 300 mg bd).</span> | |
| − | + | ||
| − | + | <span style="font-size:medium;">'''Experimental group''' (N = 22; 22 analysed): As above plus 100% oxygen for 120 mins at 2.4 ATA daily, Monday to Friday to a total of 20 treatments over four weeks.</span> | |
| + | |||
| + | '''<span style="font-size:medium;">The Evidence:</span>''' | ||
| + | |||
| + | {| | ||
|- | |- | ||
| − | | <span | + | | <span><span>'''<span>Outcome</span>'''</span></span> |
| + | | style="text-align: center;" | <span><span>'''<span>Time to Outcome</span>'''</span></span> | ||
| + | | style="text-align: center;" | <span><span>'''<span>Control Rate</span>'''</span></span> | ||
| + | | style="text-align: center;" | <span><span>'''<span>HBO Rate</span>'''</span></span> | ||
| + | | style="text-align: center;" | <span><span>'''<span>Relative risk reduction</span>'''</span></span> | ||
| + | | style="text-align: center;" | <span><span>'''<span>Absolute risk reduction</span>'''</span></span> | ||
| + | | style="text-align: center;" | <span><span>'''<span style="font-size: 10pt;">NNT</span>'''</span></span> | ||
|- | |- | ||
| − | | | + | | <span><span>'''<span>ESR normalised from start to 10 weeks</span>'''</span></span> |
| + | | style="text-align: center;" | <span><span>10 weeks</span></span> | ||
| + | | style="text-align: center;" | <span><span>0.81</span></span> | ||
| + | | style="text-align: center;" | <span><span>1.0</span></span> | ||
| + | | style="text-align: center;" | <span><span>23%</span></span> | ||
| + | | style="text-align: center;" | <span><span>0.19</span></span> | ||
| + | | <p style="text-align: center;"> </p> | ||
| + | <span><span style="display: block; font-size: 10pt; text-align: center;">5</span></span> | ||
| + | |||
|- | |- | ||
| − | | | + | | style="text-align: center;" | ^ |
| + | | style="text-align: center;" | | ||
| + | | style="text-align: center;" | | ||
| + | | style="text-align: center;" | <span><span>95% CI:</span></span> | ||
| + | | style="text-align: center;" | <span><span>3% to 44%</span></span> | ||
| + | | style="text-align: center;" | <span><span>-.02 to 0.39</span></span> | ||
| + | | style="text-align: center;" | <span><span>3 to 45</span></span> | ||
|- | |- | ||
| − | | | + | | <span><span>'''<span>CRP normalised from start to week 10</span>'''</span></span> |
| + | | style="text-align: center;" | <span><span>10 weeks</span></span> | ||
| + | | style="text-align: center;" | <span><span>0.67</span></span> | ||
| + | | style="text-align: center;" | <span><span>.73</span></span> | ||
| + | | style="text-align: center;" | <span><span>9%</span></span> | ||
| + | | style="text-align: center;" | <span><span>0.06</span></span> | ||
| + | | <p style="text-align: center;"> </p> | ||
| + | <span><span style="display: block; font-size: 10pt; text-align: center;">-17</span></span> | ||
| + | |||
|- | |- | ||
| − | | | + | | style="text-align: center;" | ^ |
| + | | style="text-align: center;" | | ||
| + | | style="text-align: center;" | | ||
| + | | style="text-align: center;" | <span><span>95% CI:</span></span> | ||
| + | | style="text-align: center;" | <span><span>-32% to 50%</span></span> | ||
| + | | style="text-align: center;" | <span><span>-0.21 to 0.33</span></span> | ||
| + | | style="text-align: center;" | <span><span>NNT 3 to INF;</span></span><br/> <span><span>NNH</span></span> 5 to INF | ||
|- | |- | ||
| − | | | + | | <span><span>'''<span>Dermatological Life Quality Index >50% improved</span>'''</span></span> |
| + | | style="text-align: center;" | <span><span>10 weeks</span></span> | ||
| + | | style="text-align: center;" | <span><span>.62</span></span> | ||
| + | | style="text-align: center;" | <span><span>1.0</span></span> | ||
| + | | style="text-align: center;" | <span><span>61%</span></span> | ||
| + | | style="text-align: center;" | <span><span>0.38</span></span> | ||
| + | | <p style="text-align: center;"> </p> | ||
| + | <span><span style="display: block; font-size: 10pt; text-align: center;">-3</span></span> | ||
| + | |||
|- | |- | ||
| + | | style="text-align: center;" | ^ | ||
| + | | style="text-align: center;" | | ||
| + | | style="text-align: center;" | | ||
| + | | style="text-align: center;" | <span><span>95% CI:</span></span> | ||
| + | | style="text-align: center;" | <span><span>27% to 95%</span></span> | ||
| + | | style="text-align: center;" | <span><span>0.17 to 0.59</span></span> | ||
| + | | style="text-align: center;" | <span><span>2 to 6</span></span> | ||
|} | |} | ||
| − | |||
| − | <span style="font-size: | + | <span style="font-size:medium;">'''Comments:'''</span> |
| + | |||
| + | <span style="font-size:medium;">1. Small open trial subject to bias for clinical score outcomes</span> | ||
| − | <span style="font-size: | + | <span style="font-size:medium;">2. Not clear that all patients received the appropriate supportive care such as help to stop smoking and to lose weight.</span> |
| − | <span style="font-size: | + | <span style="font-size:medium;">3. Control patients had longer period of illness (7 years on average versus 11 years) and this may have biased results to the HBOT group.</span> |
| − | <span style="font-size: | + | <span style="font-size:medium;">'''Appraised by:''' Michael Bennett Tuesday, 17 January 2017</span> |
| − | <span style="font-size: | + | <span style="font-size:medium;">'''Email:''' m.bennett@unsw.edu.,au ;</span> |
| − | <span style="font-size: | + | <span style="font-size:medium;">'''Kill or Update By:''' January 2020</span> |
| − | + | | |
| − | [[File: | + | [[File:Sumhorsa.gif|center|Sumhorsa.gif]] |
| − | <span style="color: #7c00ff; display: block; font-size: 26px; text-align: center;">'''[[Non- | + | <span style="color: #7c00ff; display: block; font-size: 26px; text-align: center;">'''[[Non-healing_wounds|BACK]]'''</span> |
| − | </span> | ||
Latest revision as of 01:03, 1 April 2019
The addition of hyperbaric oxygen to antibiotic treatment improved many clinical scores in patients with hydranitis suppurativa
Clinical bottom line:
| 1. Both groups improved over the course of treatment. 2. Patients with adjunctive HBOT had more chance of normalising ESR but not CRP after 10 weeks, as well as improvement in most scores assessed. |
Citation/s: 1. Yildiz H, Senol L, Ercan E, Bilgili ME, Karabudak Abuaf O. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa. International journal of dermatology. 2016;55(2):232-7.
Lead author's name and fax: Hamda Yildiz hamzayildiz@gmail.com
'Three-part Clinical Question:'For patients with hidradenitis suppurativa, does the addition of HBO to a regimen of antibiotics only, improve the rate of healing?
Search Terms: hydradenitis suppurativa, wound healing,
The Study: Non-blinded open randomised controlled trial with intention-to-treat.
The Study Patients: Adult patients newly diagnosed with hydradenitis suppurative (HS)
Control group (N = 21; 21 analysed): 10 weeks of double therapy with clindamycin (300 mg bd) and rifampicin 300 mg bd).
Experimental group (N = 22; 22 analysed): As above plus 100% oxygen for 120 mins at 2.4 ATA daily, Monday to Friday to a total of 20 treatments over four weeks.
The Evidence:
| Outcome | Time to Outcome | Control Rate | HBO Rate | Relative risk reduction | Absolute risk reduction | NNT |
| ESR normalised from start to 10 weeks | 10 weeks | 0.81 | 1.0 | 23% | 0.19 |
5 |
| ^ | 95% CI: | 3% to 44% | -.02 to 0.39 | 3 to 45 | ||
| CRP normalised from start to week 10 | 10 weeks | 0.67 | .73 | 9% | 0.06 |
-17 |
| ^ | 95% CI: | -32% to 50% | -0.21 to 0.33 | NNT 3 to INF; NNH 5 to INF | ||
| Dermatological Life Quality Index >50% improved | 10 weeks | .62 | 1.0 | 61% | 0.38 |
-3 |
| ^ | 95% CI: | 27% to 95% | 0.17 to 0.59 | 2 to 6 |
Comments:
1. Small open trial subject to bias for clinical score outcomes
2. Not clear that all patients received the appropriate supportive care such as help to stop smoking and to lose weight.
3. Control patients had longer period of illness (7 years on average versus 11 years) and this may have biased results to the HBOT group.
Appraised by: Michael Bennett Tuesday, 17 January 2017
Email: m.bennett@unsw.edu.,au ;
Kill or Update By: January 2020
